A randomised, placebo-controlled, double-blind study of adjuvant Cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma
Primary Sponsor
Collaborating Groups
TROG Cancer Research
Accrual Target
412
Final Accrual
415
Closing Date of Accrual
20 August 2024
Trial Chairperson
Prof Sandro Porceddu - Princess Alexandra Hospital
Trial Contact
qa@trog.com.au
Related Post
31 July, 2025
World Lung Cancer Day: Focus on the TROG Lung Working Party
TROG WORKING PARTY IN FOCUS: 31 July 2025 To
29 July, 2025
TROG 21.07 SOCRATES HCC Trial Expands Outreach
TRIAL IN FOCUS: 29 July 2025 We’ve extended the
